My Authors
Read all threads
THREAD (1/X) It's interesting that favipiravir (Avigan), is getting relatively little press in U.S. and western countries compared to #hydroxychloroquine (HQ). #COVID19 pilot data at least as promising as any currently available HQ data presented thus far.
3/X Currently data supporting FPV (oral) comes from a Chinese open label pilot study.
It was NOT randomized, but patients were consecutively screened, which means they weren't cherry picked. Lopinavir/ritonavir (LPVr) was used as an active control
sciencedirect.com/science/articl…
4/X The LPVr arm was enrolled THE WEEK prior from consecutive screened pts. LPVr was not shown to have benefit in COVID19 pts with severe disease, a population excluded in this FPV trial nejm.org/doi/pdf/10.105…
5/X Nonetheless, LPVr is a reasonable "historic" control, having enrolled consecutively only 1 week prior, presumably with same eligibility criteria. Both the LPVr and FPV treatment arms received inhaled interferon, so this also has to be factored into results. Study was 2 wks
6/X Baseline characteristics of FPV (N=35) and LPVr (N=45) were comparable, including viral loads (VL) at screening (Cycle threshold (Ct) values ~30). CT scans were evaluated by blinded reader using prespecified scoring system.
7/X The median time to viral clearance for the FPV and LPVr arms were 4 days vs 11 days showing statistically significant benefit for FPV
8/X On D14 there's a statistical improvement in CT Scans for FPV compared to LPVr (91% vs 62%). Importantly there was time to viral clearance (< or > 7 days) correlated with degree of improvement seen on chest CT; suggests VL is reasonable surrogate for clinical improvement
9/X FPVr was well tolerated, and has a good safety database given its approval in Japan since 2014. I would like to see clinical outcomes for patients in this study (ie hospital discharge, ICU admission, death) which I suspect will be reported when available
10/X If manufacturing can be ramped up, this FPVr may offer a good option for treatment of mild/moderate COVID19 infections, if efficacy is confirmed in Ph3 studies. It will be up to FDA and EMA to provide the appropriate authorization for patients.
2/X Favipiravir (FPV) is not approved in many countries outside of Japan, although China recently approved it for COVID-19. New trials are being conducted in multiple countries including Italy (not in U.S. yet) europost.eu/en/a/view/ital…
11/X New #favipiravir (FPV) clinical data available as of 27March suggests benefit in moderate disease #COVID19 populations. However, there are important caveats that make interpretation of this study difficult
medrxiv.org/content/10.110…
12/X The study randomizes FPV (N=116) vs active comparator arbidol (N=120). I'm not familiar with arbidol, but it appears to have a MoA of inhibiting membrane fusion. Haven't seen any data related to SARS-CoV2 activity, but its being used in China and Russia
13/X Pts had <12 days of symptoms and diagnosed as "COVID-19 pneumonia". Treatment was 7-10 d. However, it's unclear to me how many of these patients had actual infection as only 38-47% had + PCR. They DID NOT analyze data based on patients with actual + PCR and pneumonia.
14/X The study did suggest a greater improvement in clinical recovery (predefined in protocol) for FPV vs arbidol (61 vs 51%, respectively), at Day 7, that was not statistically significant for the OVERALL population (primary outcome)
15/X Most pts had moderate disease (85-90%) while the rest had severe disease. Subset analysis suggests statistical improvement in pts with moderate disease (71% vs 56%) favoring FPV. However, multiple comparisons were not accounted for so this is only hypothesis generating
16/X Severe pt population was small so limited conclusions can be made. Key limitations of study include: not analyzing data based on pts actually diagnosis (PCR +) of COVID19, not having a treatment arm with no therapy (does arbidol have activity), and inadequate power.
Missing some Tweet in this thread? You can try to force a refresh.

Enjoying this thread?

Keep Current with PD Yin

Profile picture

Stay in touch and get notified when new unrolls are available from this author!

Read all threads

This Thread may be Removed Anytime!

Twitter may remove this content at anytime, convert it as a PDF, save and print for later use!

Try unrolling a thread yourself!

how to unroll video

1) Follow Thread Reader App on Twitter so you can easily mention us!

2) Go to a Twitter thread (series of Tweets by the same owner) and mention us with a keyword "unroll" @threadreaderapp unroll

You can practice here first or read more on our help page!

Follow Us on Twitter!

Did Thread Reader help you today?

Support us! We are indie developers!


This site is made by just three indie developers on a laptop doing marketing, support and development! Read more about the story.

Become a Premium Member ($3.00/month or $30.00/year) and get exclusive features!

Become Premium

Too expensive? Make a small donation by buying us coffee ($5) or help with server cost ($10)

Donate via Paypal Become our Patreon

Thank you for your support!